Literature DB >> 31615819

Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Brendon L Neuen1, David Z Cherney1, Meg J Jardine1, Vlado Perkovic2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31615819      PMCID： PMC6791785          DOI： 10.1503/cmaj.190047

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  41 in total

1.  Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.

Authors:  Mark E Cooper; Silvio E Inzucchi; Bernard Zinman; Stefan Hantel; Maximilian von Eynatten; Christoph Wanner; Audrey Koitka-Weber
Journal:  Am J Kidney Dis       Date:  2019-06-27       Impact factor: 8.860

2.  Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.

Authors:  David Z I Cherney; Jacob A Udell
Journal:  Circulation       Date:  2016-12-13       Impact factor: 29.690

3.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

4.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

Review 5.  11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

6.  Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials.

Authors:  Richard E Gilbert; Kevin E Thorpe
Journal:  Diabetes Obes Metab       Date:  2019-05-24       Impact factor: 6.577

7.  Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.

Authors:  Mikhail Kosiborod; Carolyn S P Lam; Shun Kohsaka; Dae Jung Kim; Avraham Karasik; Jonathan Shaw; Navdeep Tangri; Su-Yen Goh; Marcus Thuresson; Hungta Chen; Filip Surmont; Niklas Hammar; Peter Fenici
Journal:  J Am Coll Cardiol       Date:  2018-03-11       Impact factor: 24.094

8.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

9.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Authors:  Brendon L Neuen; Tamara Young; Hiddo J L Heerspink; Bruce Neal; Vlado Perkovic; Laurent Billot; Kenneth W Mahaffey; David M Charytan; David C Wheeler; Clare Arnott; Severine Bompoint; Adeera Levin; Meg J Jardine
Journal:  Lancet Diabetes Endocrinol       Date:  2019-09-05       Impact factor: 32.069

10.  CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

Authors:  Ele Ferrannini; Michael Mark; Eric Mayoux
Journal:  Diabetes Care       Date:  2016-07       Impact factor: 19.112
View more
  5 in total

Review 1.  Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.

Authors:  Jinnie J Rhee; Meg J Jardine; Glenn M Chertow; Kenneth W Mahaffey
Journal:  Diabetes Obes Metab       Date:  2020-04       Impact factor: 6.577

Review 2.  Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review.

Authors:  Lisa Dubrofsky; Anand Srivastava; David Z Cherney
Journal:  Can J Kidney Health Dis       Date:  2020-06-24

3.  Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.

Authors:  Brendon L Neuen; Clare Arnott; Vlado Perkovic; Gemma Figtree; Dick de Zeeuw; Greg Fulcher; Min Jun; Meg J Jardine; Sophia Zoungas; Carol Pollock; Kenneth W Mahaffey; Bruce Neal; Hiddo J L Heerspink
Journal:  Diabetes Obes Metab       Date:  2020-10-29       Impact factor: 6.577

Review 4.  Cardiorenal Protection in Diabetic Kidney Disease.

Authors:  Jason F Lee; Ecaterina Berzan; Vikas S Sridhar; Ayodele Odutayo; David Z I Cherney
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

5.  Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies.

Authors:  Ruonan Zhai; Yuan Liu; Jiahao Tong; Ying Yu; Lin Yang; Yong Gu; Jianying Niu
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.